Merck and Moderna’s positive Phase 3 INTerpath-001 readout in August 2026 for their individualized mRNA neoantigen vaccine intismeran autogene (mRNA-4157) plus pembrolizumab drove recent sentiment, marking the first success for this approach in resected high-risk melanoma with statistically significant gains in recurrence-free and distant metastasis-free survival. The companies intend to present full data at an upcoming medical meeting and engage regulators promptly on a potential BLA filing, leveraging breakthrough therapy designation that could support submission within months. This positions the candidate ahead of competitors, including IO Biotech’s program where the FDA advised against immediate filing after a narrow Phase 3 miss, and Replimune’s RP1 which has faced multiple resubmissions. Traders are monitoring timelines for formal submission, additional trial readouts across the INTerpath program, and any shifts in FDA review priorities.